Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.
about
Future therapy of portal hypertension in liver cirrhosis - a guess.Pathobiology of liver fibrosis: a translational success storyNovel insights into the function and dynamics of extracellular matrix in liver fibrosis.Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver CirrhosisNovel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension.Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis.Effective Prevention of Liver Fibrosis by Liver-targeted Hydrodynamic Gene Delivery of Matrix Metalloproteinase-13 in a Rat Liver Fibrosis ModelEffects of Fibrotic Tissue on Liver-targeted Hydrodynamic Gene DeliveryAdipocytokines and hepatic fibrosis.Novel treatment options for portal hypertension.Status of and candidates for cell therapy in liver cirrhosis: overcoming the "point of no return" in advanced liver cirrhosis.Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.Rationale for the use of statins in liver disease.Renin angiotensin system in liver diseases: Friend or foe?Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.The calcium-activated potassium channel KCa3.1 is an important modulator of hepatic injury.The Cooperative Effect of Local Angiotensin-II in Liver with Adriamycin Hepatotoxicity on Mitochondria.Hepatic stellate cells as key target in liver fibrosis.The carbon tetrachloride model in mice.DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosisRASAL1 is a potent regulator of hepatic stellate cell activity and liver fibrosis.Hepatic stellate cell activation and pro-fibrogenic signals.Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms.Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension.Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis.Managing portal hypertension in patients with liver cirrhosis.Research progress on signaling pathways in cirrhotic portal hypertension
P2860
Q34446521-736B5708-E5B1-4B37-A155-60EC1E0890CDQ34462733-036E01CF-856E-41CC-B932-25D11BBC8657Q35622533-9613D618-3483-4609-BF86-D42005CA7FA7Q35787734-AEE8B5CC-622C-453D-B242-AEDF36D3BFA9Q36121721-8520A2A8-5D13-4C4F-9088-D38679EA7C8AQ36339714-D173ED34-9B6D-4861-9BB4-42ADB5F695D4Q37234552-21AEE2A2-30B3-4CE7-9600-43B7D15F62DEQ37256214-DA423BCD-CAE9-42CD-855B-2789C9640092Q38346026-41202FF0-66A0-414B-81C3-D79AA4F53B5CQ38680437-2783498E-7803-4264-BBD0-98FA24DDD6E1Q38820953-E01B4723-B0C9-42C0-90AE-69456D0A1F7DQ38831994-C56396DF-2159-47FC-B6EA-5E9850A3E5BAQ39171942-B8AFA23D-1C56-46BC-B2F0-C78354A01D9EQ39360840-0FB5F1B5-DB0F-44E2-97B4-29499136678FQ39429850-F16EF570-AC19-48E1-8581-B1709DB136C6Q39647330-047E0A2E-6944-4883-B9EA-B2E010028FFCQ39740192-3A45FF40-56E5-4C6A-A85E-279647BC4979Q40200602-2C9DB760-CD67-4BA5-A041-1C3F9FE1C231Q41121854-A1B80F25-21D2-4A16-9523-8011C7A14D26Q41372298-07CA204C-354E-44D9-9083-D7C643DE118FQ42371476-FA8C06B6-44D9-4313-AF29-77C3D9344571Q46347192-45662112-FB61-49F0-9EF2-09D1872F3598Q47230773-866B317D-4410-4D68-92DB-828600A1DC57Q53817185-07648B72-0174-4BBE-B90D-302BD1801AECQ53834535-0B6171BB-070A-43A0-92D1-887AE5B2E79FQ54978608-94DDC8B2-DCA0-4D77-B4C6-CDBF205006CDQ55038505-2434BE47-FDE5-487D-87D9-E2CCFE362E8EQ55278061-9E2F106A-9EA8-4FDD-B8B9-A04492F1C736Q57069571-379DB4BA-3C91-4AD7-BE9F-2A64A67D367B
P2860
Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.
@en
type
label
Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.
@en
prefLabel
Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.
@en
P2093
P2860
P50
P356
P1433
P1476
Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis.
@en
P2093
Alexandra Wojtalla
Annabelle Vogt
Benita Kowallick
Benjamin Krämer
Dieter O Fürst
Frank A Schildberg
Irela G Reza Mazar
Jacob Nattermann
Maria A Gonzalez-Carmona
Markus Linhart
P2860
P304
P356
10.1002/HEP.27117
P407
P577
2014-05-06T00:00:00Z